Transcranial Magnetic Stimulation

Learn about Transcranial Magnetic Stimulation (TMS), an FDA-cleared non-invasive brain stimulation therapy for treatment-resistant depression and OCD. Discover how rTMS and Deep TMS work, what to expect, and find qualified providers.

History and Development

Transcranial Magnetic Stimulation (TMS) emerged from decades of research into the electrical properties of the brain. The principle that magnetic fields could induce electrical currents in neural tissue was demonstrated in the 19th century, but it was not until the 1980s that modern TMS technology was developed. In 1985, Anthony Barker and colleagues at Sheffield University produced the first practical TMS device, demonstrating that a rapidly changing magnetic field delivered through a coil placed on the scalp could depolarize cortical neurons non-invasively and without the pain associated with earlier electrical stimulation methods. The introduction of repetitive TMS (rTMS), which delivers repeated pulses in rapid succession rather than single stimuli, expanded the therapeutic potential significantly, as sustained stimulation could modulate cortical excitability beyond the brief duration of a single pulse. Throughout the 1990s, researchers investigated rTMS as a potential treatment for depression, hypothesizing that stimulating the left dorsolateral prefrontal cortex, a region implicated in mood regulation and often underactive in depression, might produce therapeutic benefits. Early studies showed promising results, and a pivotal multicenter trial led by Mark George and colleagues, published in 2010, demonstrated that rTMS was significantly more effective than sham stimulation for treatment-resistant major depression. In 2008, the FDA granted clearance for TMS as a treatment for major depressive disorder in adults who had not achieved satisfactory improvement from prior antidepressant medication trials, marking the first non-invasive brain stimulation device to receive such clearance for psychiatric use. Subsequent FDA clearances expanded the indications: in 2013 for anxious depression as an adjunct treatment, in 2018 for OCD as an adjunct to standard treatment, and in 2020 for smoking cessation. Deep TMS technology, developed by BrainsWay, uses specialized H-coils that can stimulate deeper brain regions than conventional figure-eight coils, receiving FDA clearance for depression in 2013 and for OCD in 2018. Accelerated TMS protocols, including Stanford Accelerated Neuromodulation Therapy (SAINT), have been investigated as ways to deliver treatment more rapidly, with some protocols condensing the typical multi-week course into five days of intensive sessions, though these approaches remain investigational and are not yet widely available. Contemporary TMS treatment is typically delivered in an outpatient setting without anesthesia or sedation, with patients remaining awake and alert throughout each session. The field continues to evolve with ongoing research into optimal stimulation parameters, neuronavigation-guided coil placement, maintenance protocols, and applications for conditions including PTSD, bipolar depression, and substance use disorders, though many of these uses remain off-label or investigational.

Key Techniques

Standard rTMS (Repetitive Transcranial Magnetic Stimulation) - The most common TMS approach, using a figure-eight magnetic coil to deliver repeated pulses to the left dorsolateral prefrontal cortex at frequencies of 10-20 Hz, typically over 19-40 minutes per session. This is the protocol cleared by the FDA for major depressive disorder.

Deep TMS (dTMS) - A newer technology using specialized H-shaped coils that can stimulate deeper and broader brain regions than conventional coils, potentially reaching deeper cortical and subcortical structures. FDA-cleared for major depression and OCD using BrainsWay technology.

Accelerated TMS / SAINT Protocol - Emerging protocols that condense the standard treatment course into an intensive schedule, delivering multiple sessions per day over approximately five days. These approaches remain investigational and are not yet FDA-cleared or widely available.

Neuronavigation-Guided TMS - Using MRI-based navigation systems to precisely target the stimulation coil based on each individual patient's brain anatomy, improving targeting accuracy compared to standard scalp landmark-based positioning. Used in research settings and some clinical programs.

Right-Sided Inhibitory Stimulation - Delivering low-frequency (1 Hz) stimulation to the right dorsolateral prefrontal cortex, which may reduce hyperactivity in regions associated with anxiety. Sometimes used in combination with left-sided high-frequency stimulation for patients with depression and comorbid anxiety.

Motor Threshold Determination - Establishing the individualized minimum magnetic field strength needed to produce a visible thumb twitch, used to calibrate treatment intensity for each patient. This ensures the stimulation dose is tailored to each person's cortical excitability.

Maintenance TMS - Periodic follow-up sessions after the initial treatment course to sustain improvement, with protocols varying from weekly to monthly single sessions. Evidence for maintenance protocols is growing but less robust than for the initial acute course.

Adjunctive Therapy Integration - Combining TMS with ongoing psychotherapy, medication management, or other treatments to maximize and sustain benefits. TMS is not typically used as a standalone treatment but as part of a comprehensive psychiatric care plan.

Benefits

Non-Invasive and Well-Tolerated - TMS does not require anesthesia, sedation, or surgery, and patients remain awake and alert throughout treatment. Most people can drive themselves home and resume normal activities immediately after each session.

Effective for Treatment-Resistant Depression - Clinical trials demonstrate that TMS produces meaningful improvement in a significant proportion of adults with major depressive disorder who have not responded adequately to antidepressant medication, offering an option when standard treatments have failed.

Minimal Systemic Side Effects - Unlike oral antidepressant medications that circulate throughout the body, TMS delivers targeted magnetic stimulation to specific brain regions, avoiding systemic side effects such as weight gain, sexual dysfunction, gastrointestinal issues, or dry mouth.

No Reported Cognitive Impairment - Unlike electroconvulsive therapy (ECT), TMS has not been associated with memory loss or cognitive impairment, making it a preferred option for patients concerned about cognitive side effects.

Outpatient Treatment - TMS is delivered in an outpatient clinic setting without the need for hospitalization, allowing patients to maintain their daily routines and work or family responsibilities during treatment.

FDA-Cleared for Multiple Indications - TMS has received FDA clearance for major depressive disorder, anxious depression, and OCD as an adjunct treatment, providing regulatory assurance of safety and efficacy for these specific indications.

Durable Response for Many Patients - Studies suggest that a meaningful proportion of patients who respond to an acute course of TMS maintain improvement for months, with some requiring only periodic maintenance sessions rather than continuous daily treatment.

Can Be Combined with Medication - TMS can be used alongside antidepressant medications and does not require discontinuing existing pharmacotherapy, allowing for combination treatment strategies.

Treatment Steps

Step 1: Comprehensive Psychiatric Evaluation - A thorough assessment by a psychiatrist to confirm the diagnosis, document treatment resistance, review medication history, and determine whether TMS is clinically appropriate. This includes screening for contraindications such as implanted metal devices near the head, history of seizures, or certain neurological conditions.

Step 2: Insurance Authorization and Scheduling - Most insurance plans require prior authorization for TMS, which includes documentation of failed antidepressant trials. Once approved, patients schedule daily sessions typically Monday through Friday for 4-6 weeks.

Step 3: Motor Threshold Determination - At the first session, the clinician determines the patient's motor threshold, the minimum magnetic stimulation intensity needed to produce a visible involuntary hand movement. This individualized measurement calibrates the treatment dose for all subsequent sessions.

Step 4: First Treatment Session - The patient sits comfortably in a reclined chair, wearing earplugs for noise protection. The TMS coil is positioned on the scalp over the target brain region. Magnetic pulses are delivered in a series of trains with rest periods between them. Patients feel a tapping sensation on the scalp and hear a loud clicking sound from the coil.

Step 5: Daily Treatment Course - Patients return for daily sessions, typically 5 days per week for 4-6 weeks, with each session lasting approximately 19-40 minutes depending on the protocol. The stimulation parameters remain consistent across sessions, though adjustments may be made based on response and side effects.

Step 6: Progress Monitoring - Throughout the treatment course, clinicians assess symptom changes using standardized depression rating scales, track side effects, and adjust the treatment plan as needed. Response typically begins to emerge after 2-3 weeks of treatment.

Step 7: Post-Treatment Assessment and Maintenance Planning - After completing the acute course, a comprehensive evaluation determines the degree of response and whether maintenance sessions are appropriate. Patients are encouraged to continue any ongoing therapy and medication management to sustain gains.

Duration

Typically 4-6 weeks with sessions 5 days per week, for a total of approximately 20-36 sessions

Session Frequency

Daily sessions (Monday through Friday), each lasting approximately 19-40 minutes depending on the protocol

Conditions Treated

Major Depressive Disorder (FDA-Cleared) - The primary FDA-cleared indication for TMS. Intended for adults with major depressive disorder who have not achieved satisfactory improvement from one or more antidepressant medication trials at adequate dose and duration. Clinical studies show that approximately 50-60% of such patients experience meaningful symptom improvement, with roughly 30-35% achieving remission, though individual outcomes vary significantly.

Anxious Depression (FDA-Cleared, Adjunct) - FDA-cleared in 2013 as an adjunct treatment for adults with major depressive disorder who also experience anxiety symptoms. The clearance was based on data showing greater improvement in anxiety-depression measures compared to sham treatment.

Obsessive-Compulsive Disorder (FDA-Cleared, Adjunct) - FDA-cleared in 2018 as an adjunct to standard treatment (medication and/or CBT) for adults with OCD. Deep TMS using H-coil technology received this clearance. Patients should continue their existing OCD treatments, as TMS is intended to supplement, not replace, standard care.

Post-Traumatic Stress Disorder (Off-Label / Emerging) - Research into TMS for PTSD is ongoing, with some studies suggesting benefit for reducing hyperarousal and intrusive symptoms. However, TMS is not FDA-cleared for PTSD, and this use is considered off-label. Patients should discuss the evidence base with their provider.

Bipolar Depression (Off-Label) - Some studies have investigated TMS for depressive episodes in bipolar disorder, but it is not FDA-cleared for this indication. Care must be taken regarding potential mood switching, and this use should be considered off-label under specialist supervision.

Generalized Anxiety Disorder (Off-Label / Emerging) - Preliminary research suggests TMS may have benefit for treatment-resistant anxiety disorders, but it is not FDA-cleared for generalized anxiety disorder. This remains an emerging application with limited evidence.

Smoking Cessation (FDA-Cleared) - TMS received FDA clearance for smoking cessation in 2020, intended as an adjunct to behavioral therapy. This application is less commonly offered in psychiatric settings and is distinct from mental health treatment indications.

Treatment-Resistant Depression - TMS is specifically designed for patients whose depression has not responded adequately to standard treatments, making it an important option in the treatment-resistant depression care pathway. It does not require discontinuing existing antidepressant medications.

Risks

Scalp Discomfort - The most common side effect is temporary discomfort, tingling, or a tapping sensation at the treatment site on the scalp during stimulation. Most patients adapt to this sensation over the first few sessions, and it typically resolves shortly after each session ends.

Headache - Some patients experience mild to moderate headaches during or after treatment sessions, particularly in the first week. These are typically manageable with over-the-counter pain relievers and tend to decrease in frequency as treatment progresses.

Facial Muscle Twitching - Magnetic pulses may cause involuntary twitching of facial muscles, particularly around the eyes or jaw, during stimulation. This is temporary, occurs only during active pulsing, and is not harmful.

Rare Seizure Risk - Seizures are a rare but serious potential risk of TMS. Large-scale registries estimate the risk at less than 0.1% of patients, comparable to the baseline seizure risk in the general population. TMS is contraindicated in individuals with a history of seizures or epilepsy unless specifically cleared by a neurologist.

Hearing Changes - The TMS device produces loud clicking sounds during stimulation. Patients are required to wear earplugs to protect hearing, and temporary changes in hearing threshold have been reported in rare cases when ear protection is not used properly.

Treatment Ineffectiveness - Not all patients respond to TMS. Approximately 40-50% of patients with treatment-resistant depression do not achieve meaningful improvement. Response cannot be reliably predicted before treatment, and non-response does not guarantee that other treatments will also fail.

Cost and Access Barriers - TMS treatment can be expensive, and while many insurance plans now provide coverage for FDA-cleared indications, prior authorization requirements are often stringent. Patients may need to document multiple failed medication trials before coverage is approved.

Time Commitment - The standard treatment course requires daily visits (typically 5 days per week) for 4-6 weeks, which can be logistically challenging for patients who work or have caregiving responsibilities. This time burden should be considered when evaluating treatment options.

Success Rate and Testimonials

Clinical research indicates that approximately 50-60% of adults with treatment-resistant depression experience meaningful symptom improvement following a full course of TMS, with roughly 30-35% achieving full remission. These figures come from controlled trials and large clinical registries, but individual response varies and cannot be guaranteed. For OCD, FDA clearance was based on data showing greater improvement with Deep TMS compared to sham treatment when used as an adjunct to standard care. Response rates for off-label uses (PTSD, bipolar depression, anxiety disorders) are less well-established. Maintenance of improvement after the acute course varies; some patients maintain gains for months or longer with periodic maintenance sessions, while others may experience symptom return and require repeat treatment.

"After years of trying different antidepressants with limited success, my psychiatrist recommended TMS. I was nervous about the daily commitment, but each session was short and I could go right back to work afterward. By the third week, I started noticing small changes, brighter moods, more energy, less of that heavy fog. By the end of the six-week course, I felt like myself again for the first time in years. It wasn't an overnight fix, but it gave me a foundation to build on with my ongoing therapy and medication."

Treatment Approaches

Advantages

Non-invasive with no anesthesia or sedation required
No systemic side effects like weight gain or sexual dysfunction
No reported cognitive impairment or memory loss
Outpatient treatment with no recovery time needed
FDA-cleared for depression, anxious depression, and OCD
Can be combined with existing medications and therapy

Limitations

Requires daily visits for 4-6 weeks, which can be logistically challenging
Not all patients respond; roughly 40-50% do not achieve meaningful improvement
May require maintenance sessions to sustain benefits
Insurance authorization can be difficult to obtain
Contraindicated for patients with certain implanted metal devices in the head
Off-label uses for PTSD, anxiety, and bipolar depression lack FDA clearance

Frequently Asked Questions

What is Transcranial Magnetic Stimulation (TMS) and how does it work?

TMS is a non-invasive brain stimulation therapy that uses focused magnetic pulses to modulate activity in specific brain regions involved in mood regulation. A magnetic coil placed on the scalp delivers rapidly changing magnetic fields that induce small electrical currents in the cortical tissue beneath the coil. For depression, the coil is typically positioned over the left dorsolateral prefrontal cortex, a region that is often underactive in depression. Repeated stimulation over several weeks is thought to normalize neural activity and connectivity in mood-regulating circuits. The treatment does not require anesthesia, and patients remain awake and alert throughout each session.

Is TMS the same as electroconvulsive therapy (ECT)?

No. TMS and ECT are fundamentally different treatments. ECT requires general anesthesia and induces a controlled seizure to achieve its therapeutic effects, and it is associated with potential memory side effects. TMS is non-invasive, does not require anesthesia or sedation, does not induce seizures (except in extremely rare cases), and has not been associated with memory loss or cognitive impairment. TMS is typically considered for patients with treatment-resistant depression who have not responded to medications but may not need or want the intensity of ECT.

How long is a TMS treatment course and what does each session involve?

A standard acute TMS course for depression typically runs 4-6 weeks with sessions 5 days per week (Monday through Friday), for a total of approximately 20-36 sessions. Each session lasts about 19-40 minutes depending on the specific protocol and device used. Patients sit in a reclined chair, wear earplugs, and remain awake throughout. They feel a tapping sensation on the scalp and hear a loud clicking sound from the coil. Most patients can drive home and return to normal activities immediately after each session.

What conditions is TMS FDA-cleared to treat?

TMS has received FDA clearance for three mental health indications: major depressive disorder in adults who have not responded adequately to antidepressant medication (2008), anxious depression as an adjunct treatment (2013), and obsessive-compulsive disorder as an adjunct to standard treatment using Deep TMS technology (2018). TMS has also received FDA clearance for smoking cessation (2020). Uses for PTSD, bipolar depression, generalized anxiety disorder, and other conditions remain off-label or investigational and should be discussed with a qualified provider.

Does TMS have side effects?

TMS is generally well-tolerated. The most common side effects are temporary scalp discomfort or tingling at the treatment site and mild headaches, both of which typically resolve on their own and decrease over the first week of treatment. Facial muscle twitching during stimulation is also common but harmless. Rare but serious risks include seizure (estimated at less than 0.1% of patients) and temporary hearing changes if ear protection is not worn. TMS does not cause the systemic side effects associated with oral antidepressants, such as weight gain, sexual dysfunction, or gastrointestinal problems.

Will I need to stop my current medications to do TMS?

No. TMS can be used alongside your current antidepressant medications, and most providers recommend continuing existing pharmacotherapy during the TMS course. TMS works through a different mechanism than medication, and the two approaches may be complementary. Your psychiatrist will review your medication regimen and make recommendations about whether any changes are appropriate.

Related Therapies & Approaches

Depression Treatment

Therapeutic and medical care for individuals struggling with depression.

Learn More

Anxiety Treatment

Targeted interventions to manage and reduce anxiety symptoms.

Learn More

OCD Treatment

Evidence-based therapy for obsessive-compulsive disorder using exposure and response prevention.

Learn More

Ketamine Therapy

Innovative treatment using ketamine to rapidly reduce depression and suicidal thoughts.

Learn More

Psychiatric Services

Medical evaluation, diagnosis, and medication management by psychiatrists.

Learn More

Find Transcranial Magnetic Stimulation by State

Browse transcranial magnetic stimulation providers across all 50 states and Washington, D.C.

Facilities Offering Transcranial Magnetic Stimulation

Browse mental health facilities that offer Transcranial Magnetic Stimulation and explore care options across the United States.

Find Mental Health Treatment Near You

Search mental health facilities and treatment centers by location, insurance, and available services.